Advertisement
Advertisement
BMY
Bristol-Myers Squibb Co.
59.60
USDSponsored
-2.13
-3.44%
Apr 02, 15:59 UTC -4
Closed
After-Market
59.58
-0.03
-0.05%
BMY Earnings Reports
Positive Surprise Ratio
BMY beat 35 of 40 last estimates.
88%
Next Report
Date of Next Report
Apr 30, 2026
Estimate for Q1 26 (Revenue/ EPS)
$10.95B
/$1.45
Implied change from Q4 25 (Revenue/ EPS)
-12.38%
/+15.08%
Implied change from Q1 25 (Revenue/ EPS)
-2.20%
/-19.44%
Bristol-Myers Squibb Co. earnings per share and revenue
On Feb 05, 2026, BMY reported earnings of 1.26 USD per share (EPS) for Q4 25, beating the estimate of 1.12 USD, resulting in a 11.85% surprise. Revenue reached 12.50 billion, compared to an expected 12.40 billion, with a 0.79% difference. The market reacted with a +3.30% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 11 analysts forecast an EPS of 1.45 USD, with revenue projected to reach 10.95 billion USD, implying an increase of 15.08% EPS, and decrease of -12.38% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nanobiotix S.A. - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.55
Actual
-$0.39
Surprise
-170.16%
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Cyclerion Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.21
Surprise
+45.82%
Femasys Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.80%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$2.02
Surprise
-68.69%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.24
Actual
-$0.16
Surprise
+34.64%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Bristol-Myers Squibb Co.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Bristol-Myers Squibb Co. reported EPS of $1.26, beating estimates by 11.85%, and revenue of $12.50B, 0.79% above expectations.
How did the market react to Bristol-Myers Squibb Co.'s Q4 2025 earnings?
The stock price moved up 3.3%, changed from $57.62 before the earnings release to $59.52 the day after.
When is Bristol-Myers Squibb Co. expected to report next?
The next earning report is scheduled for Apr 30, 2026.
What are the forecasts for Bristol-Myers Squibb Co.'s next earnings report?
Based on 11
analysts, Bristol-Myers Squibb Co. is expected to report EPS of $1.45 and revenue of $10.95B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement